CR20210481A - Formulación sólida del modulador de ensamblaje de la cápside - Google Patents

Formulación sólida del modulador de ensamblaje de la cápside

Info

Publication number
CR20210481A
CR20210481A CR20210481A CR20210481A CR20210481A CR 20210481 A CR20210481 A CR 20210481A CR 20210481 A CR20210481 A CR 20210481A CR 20210481 A CR20210481 A CR 20210481A CR 20210481 A CR20210481 A CR 20210481A
Authority
CR
Costa Rica
Prior art keywords
capsid assembly
solid formulation
assembly modulator
modulator
capsid
Prior art date
Application number
CR20210481A
Other languages
English (en)
Spanish (es)
Inventor
Claire Elisabeth Balmain
Oliver Lenz
Abhishek Singh
Dominique Josiane W Verstraete
Joris Jozef Vandenbossche
Michaël Bertil S Anné
Maria Jansens
Jan Snoeys
Dycke Frederic Anne R Van
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/352,754 external-priority patent/US10973801B2/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of CR20210481A publication Critical patent/CR20210481A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CR20210481A 2019-03-13 2020-03-13 Formulación sólida del modulador de ensamblaje de la cápside CR20210481A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2019056348 2019-03-13
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
PCT/IB2019/000231 WO2019175657A1 (fr) 2018-03-14 2019-03-13 Schéma posologique de modulateur d'assemblage de capside
EP19197566 2019-09-16
PCT/EP2020/056991 WO2020183020A1 (fr) 2019-03-13 2020-03-13 Formulation solide de modulateur d'assemblage de capside

Publications (1)

Publication Number Publication Date
CR20210481A true CR20210481A (es) 2021-10-25

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210481A CR20210481A (es) 2019-03-13 2020-03-13 Formulación sólida del modulador de ensamblaje de la cápside

Country Status (16)

Country Link
EP (1) EP3937928A1 (fr)
JP (1) JP2022524819A (fr)
KR (1) KR20210137484A (fr)
CN (1) CN113557016A (fr)
AU (1) AU2020235442A1 (fr)
BR (1) BR112021017525A2 (fr)
CA (1) CA3132095A1 (fr)
CR (1) CR20210481A (fr)
EC (1) ECSP21067052A (fr)
IL (1) IL286209A (fr)
JO (1) JOP20210250A1 (fr)
MA (1) MA55280A (fr)
MX (1) MX2021011030A (fr)
PE (1) PE20212107A1 (fr)
SG (1) SG11202109710QA (fr)
WO (1) WO2020183020A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3442524A2 (fr) 2016-04-15 2019-02-20 Novira Therapeutics Inc. Associations et méthodes comprenant un inhibiteur d'ensemble capside
EA202092171A1 (ru) * 2018-03-14 2020-12-01 Янссен Сайенсиз Айрлэнд Анлимитед Компани Схема дозирования модулятора сборки капсида

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EA202092171A1 (ru) * 2018-03-14 2020-12-01 Янссен Сайенсиз Айрлэнд Анлимитед Компани Схема дозирования модулятора сборки капсида

Also Published As

Publication number Publication date
MX2021011030A (es) 2021-10-13
JOP20210250A1 (ar) 2023-01-30
CA3132095A1 (fr) 2020-09-17
PE20212107A1 (es) 2021-11-04
CN113557016A (zh) 2021-10-26
KR20210137484A (ko) 2021-11-17
SG11202109710QA (en) 2021-10-28
ECSP21067052A (es) 2021-11-18
EP3937928A1 (fr) 2022-01-19
MA55280A (fr) 2022-01-19
JP2022524819A (ja) 2022-05-10
WO2020183020A1 (fr) 2020-09-17
AU2020235442A1 (en) 2021-08-12
IL286209A (en) 2021-10-31
BR112021017525A2 (pt) 2021-11-23

Similar Documents

Publication Publication Date Title
PH12020551421A1 (en) Capsid assembly modulator dosing regimen
ZA202500439B (en) Therapeutic compounds for hiv virus infection
MX383447B (es) Combinación de un inhibidor de ensamblaje de cápsido y peginterferón alfa-2a y sus usos para tratar infecciones por virus de la hepatitis b (vhb).
MX2020011808A (es) Combinaciones y metodos que comprenden un inhibidor del ensamblaje de la capside.
UA117518C2 (uk) 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b
GEP20146134B (en) Inhibitors of hepatitis c virus replication
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
PH12019550113A1 (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EA201892034A1 (ru) Элиминация вируса гепатита в при помощи противовирусных агентов
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
EA201591220A1 (ru) Новые противовирусные агенты против инфекции вирусом гепатита в
EA201890200A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
NZ739248A (en) Inhibitors of hepatitis c virus
MX2018005729A (es) Composiciones terapeuticas para tratamiento del virus de inmunodeficiencia humana.
CR20210481A (es) Formulación sólida del modulador de ensamblaje de la cápside
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
MX2022007909A (es) Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
HK40083224A (zh) 乙型肝炎病毒相关疾病的治疗
MX2019009659A (es) Dosis mejorada de baloxavir marboxil para pacientes pediatricos.
EA202192969A1 (ru) Новые оксалилпиперазины, активные против вируса гепатита b (вгв)
EA202192967A1 (ru) Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв)
MX2019015236A (es) Uso de la rpobenecida y sus derivados como inhibidores de la neuraminidasa del virus de la influenza.
EA202191109A1 (ru) Соединения 5-членного гетероарилкарбоксамида для лечения вируса гепатита в
EA201892348A1 (ru) Комбинации и способы, включающие ингибитор сборки капсида